MIRA INFORM REPORT

 

 

Report No. :

340568

Report Date :

11.09.2015

 

IDENTIFICATION DETAILS

 

Name :

BRAINFARMA INDUSTRIA QUIMICA E FARMACÊUTICA S/A

 

 

Registered Office :

Estrada Dos Bandeirantes, 3191 Parte I – Jacarepaguá 22775-111 - Rio De Janeiro/RJ

 

 

Country :

Brazil

 

 

Financials (as on) :

31.12.2014

 

 

Date of Incorporation :

24.06.2002

 

 

Legal Form :

Privately Held Corporation

 

 

Line of Business :

Manufacture of Pharmaceutical Products.

 

 

No. of Employees :

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Brazil

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


 

BRAZIL - ECONOMIC OVERVIEW

 

Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, and a rapidly expanding middle class, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. Since 2008, Brazil became a net external creditor and all three of the major ratings agencies awarded investment grade status to its debt. After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. Unemployment is at historic lows and Brazil's traditionally high level of income inequality has declined for each of the last 15 years. Rising inflation led the authorities to take measures to cool the economy in 2011; these actions and the deteriorating international economic situation slowed growth in 2011-14. Brazil’s fiscal and current account balances have eroded during the past three years as the government attempted to boost economic growth through targeted tax cuts for industry and incentives to spur household consumption. President Dilma ROUSSEFF has indicated that her government in her second term will pursue more austere fiscal policies to reduce these imbalances and preserve the country’s credit rating.

 

Source : CIA

 

Company Name

 

BRAINFARMA INDUSTRIA QUIMICA E FARMACÊUTICA S/A

 

 

ADDRESSES

 

MAIN ADDRESS:

ESTRADA DOS BANDEIRANTES,3191 PARTE I - JACAREPAGUÁ

ZIP CODE/CITY:

22775-111 - RIO DE JANEIRO/RJ

 

 

PHONE:

21 2126-3000

FAX:

21 2126-3000

E-MAIL:

joao.malecaesk@hipermarcas.com.br

WEB SITE:

www.brainfarma.com.br

 

BRANCHES:

 

 

 

ADDRESS:

V PR-1, S/Nº,0 QUADRA 2-A MODULO 4 - DISTRITO AGROINDUSTRIAL DE ANAPOLIS

ZIP CODE/CITY:

75132-020 ANAPOLIS/GO

PHONE:

62 3623-2209

 

 

LEGAL DATA

 

MAIN ACTIVITIES:

 

MANUFACTURE OF PHARMACEUTICAL PRODUCTS

 

LEGAL FORM:

PRIVATELY HELD CORPORATION

 

 

INCORPORATION DATE:

24/06/2002

REGISTER DATE:

24/06/2002

BALANCE SHEET FILING DATE:

31/12

TAX CONTRIBUTOR NUMBER(CNPJ):

05.161.069/0001-10

STATE REGISTER:

77.462.406

 

 

SHARE CAPITAL:

R$ 476.021.191,95

LAST REGISTER OF CAPITAL:

13/06/2014

 

BOARD OF DIRECTORS:

 

 

 

SILVIO TADEU AGOSTINHO

DIRECTOR

BRENO TOLEDO PIRES DE OLIVEIRA

DIRECTOR

CARLOS ROBERTO SCORSI

DIRECTOR

AMARAI FURTADO DA SILVA

DIRECTOR

ARMANDO LUIS FERREIRA

DIRECTOR

 

 

AUTHORIZED USE OF SIGNATURE

 

THE DIRECTORS ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY.

 

 

SHAREHOLDERS / PARTNERS:

 

 

 

HYPERMARCAS S/A

100%

 

AFFILIATES / SUBSIDIARIES:

 

A SCAN THROUGH OUTSIDE SOURCES SHOWED THE SUBJECT AND/OR DIRECTORS HAS/HAVE THE FOLLOWING UNCONFIRMED HOLDINGS:

 

 

MANTECORP INDUSTRIA QUIMICA E FARMACEUTICA S/A

 

I P H C INDUSTRIA DE PRODUTOS DE HIGIENE E COSMETICOS LTDA

 

COSMED INDUSTRIA DE COSMETICOS E MEDICAMENTOS S/A

 

MY AGENCIA DE PROPAGANDA LTDA

 

EAAPAR ADMINISTRAÇÃO E PARTICIPAÇÕES LTDA

 

FAZENDA TANGURO AGROPECUARIA S/A

 

YORK S/A INDUSTRIA E COMERCIO

 

 

 

COMPANY'S BACKGROUND

 

 

THE SUBJECT WAS ESTABLISHED ON JUNE 24, 2002 AS BRAINFARMA INDUSTRIA QUIMICA E FARMACEUTICA LTDA TO BE ENGAGED IN THE SAID LINE OF BUSINESS. ON APRIL 13, 2011 IT WAS TRANSFORMED INTO STOCK COMPANY UNDER THE ABOVE MENTIONED NAME.

 

ACCORDING TO STOCKHOLDERS' GENERAL MEETING HELD ON APRIL 29, 2011, THE PARTIAL SPLIT-OFF OF HYPERMARCAS S.A. WAS APPROVED. THE SPUN OFF NET ASSETS WERE MERGED INTO COSMED INDÚSTRIA DE COSMÉTICOS E MEDICAMENTOS S.A. AND BRAINFARMA INDÚSTRIA QUÍMICA E FARMACÊUTICA S.A. CONCURRENTLY, HYPERMARCAS S/A ALSO MERGED THE SHARES ISSUED BY COSMED AND BRAINFARMA SO THAT THESE COMPANIES COULD REMAIN WHOLLY-OWNED SUBSIDIARIES OF HYPERMARCAS S/A, AND THE NUMBER OF SHARES AND THE SHARE CAPITAL OF HYPERMARCAS REMAINED THE SAME AS THOSE PRIOR TO THE SPLIT-OFF.

 

IN APRIL 2011 SUBJECT TOOK OVER THE SPUN-OFF PART OF THE NET EQUITY OF LABORATORIO NEO QUIMICA COMERCIO E INDUSTRIA S/A.

 

TRADE NAME: BRAINFARMA

 

FURTHER DETAILS ARE SO FAR NOT KNOWN.

 

PUBLIC INFORMATION:

 

NO DETRIMENTAL FILES WERE FOUND.

 

 

FINANCIAL INFORMATION

 

GENERAL BALANCE SHEETS AS OF 31/12/2014, 31/12/2013 AND 31/12/2012.

( FIGURES ARE IN THOUSANDS OF REAIS ).

 

ASSETS

 

 

 

CURRENT:

31/12/2014

31/12/2013

31/12/2012

 

 

 

 

CASH AND CASH EQUIVALENTS

103.030

110.874

232.256

CLIENTS

79.187

64.857

36.294

INVENTORY

211.451

152.731

89.666

RECOVERABLE TAXES

994

7.081

 

OTHER CREDITS

6.432

37.071

4.176

CREDIT WITH RELATED PARTIES

49.466

45.993

 

DERIVATIVES OPERATIONS

6.459

 

 

 

----------------

----------------

----------------

TOTAL CURRENT ASSETS

457.019

418.607

362.392

 

LONG-TERM RECEIVABLES:

 

 

 

 

 

 

 

INTERCOMPANY CREDITS

1.039

1.199

949

RECOVERABLE TAXES

11.304

8.670

6.386

OTHER CREDITS

1.622

1.374

1.366

 

----------------

----------------

----------------

TOTAL LONG-TERM RECEIVABLES

13.965

11.243

8.701

 

FIXED ASSETS:

 

 

 

 

 

 

 

FIXED ASSETS

439.718

389.083

349.492

INTANGIBLE

68.970

70.312

63.563

 

----------------

----------------

----------------

TOTAL FIXED ASSETS

508.688

459.395

413.055

 

================

================

================

TOTAL ASSETS

979.672

889.245

784.148

 

LIABILITIES:

 

 

 

CURRENT:

31/12/2014

31/12/2013

31/12/2012

 

 

 

 

SUPPLIERS

187.053

152.462

95.141

LOANS AND FINANCING

29.415

21.361

22.458

SOCIAL / LABOR OBLIGATIONS

33.784

23.037

13.756

ACCOUNTS PAYABLE

12.031

13.877

7.860

TRIBUTARY OBLIGATIONS

9.016

9.393

8.361

INCOME TAX/SOCIAL CONTRIBUTION

5.693

3.015

 

DIVIDENDS

20.205

7.697

 

 

----------------

----------------

----------------

TOTAL CURRENT LIABILITIES

297.197

230.842

147.576

 

LONG TERM LIABILITIES:

 

 

 

 

 

 

 

LOANS AND FINANCING

117.287

72.592

82.817

RELATED COMPANIES

61

164

11.354

DEFERRED TAXES

33.917

33.933

23.693

OTHER

787

4.416

4.527

PROVISION FOR CONTINGENCIES

2.166

748

61

 

----------------

----------------

----------------

TOTAL LONG TERM LIABILITIES

154.218

111.853

122.452

 

NET EQUITY:

 

 

 

 

 

 

 

SHARE CAPITAL

476.021

488.961

487.931

CAPITAL RESERVES

4.363

3.251

2.139

OTHER COMPREHENSIVE INCOME

29.644

29.628

29.644

PROFIT RESERVES

3.639

1.620

 

ACCRUED PROFIT (LOSS)

14.590

23.090

-5.594

 

----------------

----------------

----------------

TOTAL NET EQUITY

528.257

546.550

514.120

 

================

================

================

TOTAL LIABILITIES

979.672

889.245

784.148

 

PROFIT AND LOSS ACCOUNTS AS OF 31/12/2014, 31/12/2013 AND 31/12/2012.

(FIGURES ARE IN THOUSANDS OF REAIS ).

 

 

31/12/2014

31/12/2013

31/12/2012

 

 

 

 

NET SALES

659.612

517.235

424.818

(-) COST OF SOLD GOODS

524.536

430.243

360.201

 

----------------

----------------

----------------

GROSS PROFIT

135.076

86.992

64.617

OPERATING REVENUE (EXPENSE)

-77.367

-50.651

-67.885

FINANCIAL REVENUE(EXPENSE)

-6.751

18.207

-2.695

 

----------------

----------------

----------------

OPERATIONAL PROFIT (LOSS)

50.958

54.548

-5.963

CONTRIBUTION/INCOME TAX

-6.272

-16.547

369

 

----------------

----------------

----------------

NET PROFIT (LOSS)

44.686

38.001

-5.594

 

RATIOS:

31/12/2014

31/12/2013

31/12/2012

 

QUICK RATIO

,83

 

1,15

 

1,85

 

CURRENT RATIO

1,54

 

1,81

 

2,46

 

ACCOUNTS RECEIVABLE TURNOVER

8,33

TIMES

7,98

TIMES

11,70

TIMES

DAYS' SALES IN RECEIVABLES

43,22

DAYS

45,14

DAYS

30,76

DAYS

INVENTORY TURNOVER

2,48

TIMES

2,82

TIMES

4,02

TIMES

ACCOUNTS PAYABLE PERIOD

128,38

DAYS

127,57

DAYS

95,09

DAYS

RETURN ON ASSETS

,67

TIMES

,58

TIMES

,54

TIMES

SALES TURNOVER ON NET EQUITY

1,25

TIMES

,95

TIMES

,83

TIMES

NET WORTH TIE-UP

,83

 

,71

 

,68

 

INDEBTEDNESS

,85

 

,63

 

,53

 

EQUITY RATIO

53,92

%

61,46

%

65,56

%

WORKING CAPITAL RATIO

53,78

%

81,34

%

145,56

%

GENERAL SOLVENCY

2,17

 

2,59

 

2,90

 

RETURN ON NET EQUITY

8,46

%

6,95

%

-1,09

%

RETURN ON SALES (PROFIT MARGIN)

6,77

%

7,35

%

-1,32

%

GROSS PROFIT MARGIN

20,48

%

16,82

%

15,21

%

OPERATIONAL RESULT

7,73

%

10,55

%

-1,40

%

SALES TURNOVER ON LIABILITIES

2,22

TIMES

2,24

TIMES

2,88

TIMES

FOREIGN CURRENCY ON ASSETS

 

 

 

 

 

 

FOREIGN CURRENCY ON LIABILITIES

 

 

 

 

 

 

 

EXCHANGE RATE:

 

 

US$ 1,00 = R$ 3,02

 - OFFICIAL RATE ON 16/04/2015

US$ 1,00 = R$ 2,65

 - OFFICIAL RATE ON 31/12/2014

US$ 1,00 = R$ 2,34

 - OFFICIAL RATE ON 31/12/2013

US$ 1,00 = R$ 2,04

 - OFFICIAL RATE ON 31/12/2012

 

COMMENTS ON THE FINANCIAL INFORMATION:

 

FOLLOWS ATTACHED WORKSHEET WITH MAIN FINANCIAL RATIOS

 

THE FIGURES AVAILABLE SHOW A GOOD FINANCIAL STANDING. IT HAS GOOD LIQUIDITY RATIOS AND GOOD WORKING CAPITAL, AS WELL AS ACCEPTABLE LEVEL OF INDEBTEDNESS. IT ALSO SHOWS GROWING SALES AND POSTED PROFIT.

 

IT IS WORTH COMMENTING THAT THE SUBJECT IS CONTROLLED BY THE HYPERMARCAS GROUP, WHICH HAS VERY HIGH FINANCIAL POWER THUS MAY GIVE THE SUBJECT THE NECESSARY FINANCIAL POWER.

 

REAL ESTATE:

 

OWNED PREMISES ARE VALUED AT R$ 162.994.000,00

 

VEHICLES:

 

OWNED VEHICLES ARE VALUED AT R$ 270.000,00

 

MACHINES:

 

OWNED MACHINES AND EQUIPMENTS ARE VALUED AT R$ 221.296.000,00

 

 


INSURANCE

 

NOT AVAILABLE.

 

 

BANKING REFERENCES

 

NOT AVIALABLE

 

 

 

REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS.

 

ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS NOT RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK").

 

 

ACTIVITIES COMMENTS

 

THE SUBJECT IS ENGAGED IN THE MANUFACTURE OF FARMACEUTICALS.

 

IMPORT AND EXPORT:

 

IMPORTS FROM:

NOT AVAILABLE.

 

EXPORTS TO:

NOT AVAILABLE.

 

MAIN CLIENTS:

 

 

 

 

 

DOMESTIC CLIENTS:

 

 

*PRINCIPAIS DISTRIBUIDORES

 

 

ALTO MIUDEZAS

 

 

AMERICAN FARMA

 

 

ANB

 

 

ATHOS

 

 

AUDIFAR

 

 

CENTRO AMERICA

 

 

DROGUISTAS

 

 

FARMED

 

 

IMIFARMA

 

 

JORGE BATISTA

 

 

NAZÁRIA

 

 

PANARELLO

 

 

RECOL

 

 

SANTA CRUZ

 

 

SB LOG

 

 

SERVIMED

 

 

SUDESTEFARMA

 

 

TAPAJÓS

 

 

 

STAFF:

 

NOT AVAILABLE

 

 

CONCEPT AND FULFILMENT

 

THE SUBJECT IS A WELL-ESTABLISHED SUBSIDIARY OF THE HYPERMARCAS GROUP, OPERATING SINCE 2002. SO FAR IT HAS A CLEAR TRADE HISTORY AND GOOD PAYMENT BEHAVIOR.

 

THE COMPANY HAS TRADE RELATIONS WITH SEVERAL SUPPLIERS IN BRAZIL. THE SUPPLIERS EXTEND CREDIT FACILITIES TO THE SUBJECT IN TERMS AND AMOUNTS ACCORDING TO THE COMPANY'S NEEDS AND SO FAR NO PAYMENT PROBLEMS ARE NOTED.

 

MAIN SUPPLIERS:

 

 

 

 

 

DOMESTIC SUPPLIERS:

 

 

NOT AVIALABLE

 

 

 

PAYMENT HISTORY:

 

18 SUPPLIERS REPORTED PAYMENTS:

   TOTAL AMOUNT:  R$ 2.150.484,00

 

AMOUNT OF INVOICES PAID: 176

TOTAL OF PROMPT PAYMENTS: 92,6%

TOTAL OF DELAYED PAYMENTS: 7,4%

 

HIGHEST INVOICE: R$ 107.728,00

HIGHEST CREDIT: R$ 107.728,00

 

OUTSTANDING INVOICES DUE WITHIN THE NEXT 91 DAYS:

 

---------------------------

SUPPLIERS:

INVOICES:

TOTAL AMOUNT:

DUE WITHIN 30 DAYS

2

13

R$ 29.680,84

DUE WITHIN 60 DAYS

2

25

R$ 43.273,25

DUE WITHIN 90 DAYS

2

18

R$ 52.077,47

DUE WITHIN 91 DAYS

1

18

R$ 46.575,60

 

 

FINAL OPINION

 

THE SUBJECT IS A WELL-ESTABLISHED COMPANY IN BUSINESS SINCE 2002. IT HAS JUST BEEN ACQUIRED BY HYPERMARCAS GROUP, WHICH HAS VERY HIGH FINANCIAL POWER, THUS MAY GIVE THE SUBJECT THE NECESSARY FINANCIAL SUPPORT WHENEVER REQUIRED. UP TO DATE IT HAS A SATISFACTORY FINANCIAL STANDING, A CLEAR TRADE HISTORY AND GOOD PAYMENT BEHAVIOR.

 

BASED ON THE GENERAL INFORMATION AVAILABLE IT IS BELIEVED THAT GOOD TRADE RELATIONS MAY BE ESTABLISHED. CREDIT FACILITIES MAY BE EXTENDED WITHIN TERMS AND AMOUNTS ADEQUATE TO THE COMPANY'S FINANCIAL STRENGTH.

 

HIGHER AMOUNTS CAN BE GRANTED DEPENDING ON THE IMPORTANCE OF THE ACTIVITIES BEING ESTABLISHED WITH THE SUBJECT.

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.66.58

UK Pound

1

Rs.102.29

Euro

1

Rs.74.71

 

INFORMATION DETAILS

 

Analysis Done by :

SUB

 

 

Report Prepared by :

NIT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.